YAP Inhibitors

The Yes-associated protein (YAP) is a central downstream effector of the Hippo signaling pathway, which is a critical regulator of organ size, tissue regeneration, and cellular proliferation. When the Hippo pathway is 'on,' upstream kinases like MST1/2 and LATS1/2 phosphorylate YAP, leading to its cytoplasmic sequestration and degradation. However, when the pathway is 'off' or dysregulated, YAP translocates to the nucleus, where it acts as a transcriptional co-activator. Since YAP lacks a DNA-binding domain, it primarily interacts with the TEA domain (TEAD) family of transcription factors to drive the expression of genes involved in cell survival, epithelial-mesenchymal transition (EMT), and stemness. Dysregulation of YAP is a common feature in many human cancers, including mesothelioma, hepatocellular carcinoma, gastric cancer, and squamous cell carcinomas. Beyond its role in primary tumorigenesis, YAP is increasingly recognized as a key mediator of resistance to conventional chemotherapies and targeted agents, such as EGFR and BRAF inhibitors.

Inhibiting YAP presents a significant therapeutic opportunity but also poses substantial challenges due to its nature as a protein-protein interaction (PPI) target rather than an enzyme. Current research progress has identified several classes of inhibitors. Verteporfin, a benzoporphyrin derivative used in photodynamic therapy, was one of the first compounds identified to inhibit YAP-TEAD interaction, although its clinical utility is limited by poor potency and specificity. More recently, small molecules like TED-347 and various TEAD autopalmitoylation inhibitors (e.g., VT-101, IK-930) have entered preclinical and early clinical development. These compounds target the palmitoylation pocket of TEAD, which is essential for its stability and interaction with YAP. Another strategy involves the use of peptide mimetics that disrupt the YAP-TEAD interface.

YAP inhibitors can be classified into direct PPI disruptors, TEAD palmitoylation inhibitors, and indirect inhibitors that target upstream regulators or downstream effectors. A major challenge in the field is the potential for toxicity, as YAP is essential for normal tissue homeostasis and wound healing. Furthermore, the lack of a traditional catalytic pocket on YAP makes the design of high-affinity small molecules difficult. Current research is also exploring the role of YAP in the tumor microenvironment, where it influences the recruitment of myeloid-derived suppressor cells. Combination therapies, particularly those pairing YAP inhibitors with MAPK pathway inhibitors, are being investigated to prevent the emergence of drug resistance. As the structural biology of the YAP-TEAD complex becomes better understood, the development of more potent and selective inhibitors is expected to accelerate, potentially offering new hope for patients with Hippo-deficient or YAP-driven malignancies.